Direct activation of PP2A for the treatment of tyrosine kinase inhibitor–resistant lung adenocarcinoma

Although tyrosine kinase inhibitors (TKIs) have demonstrated significant efficacy in advanced lung adenocarcinoma (LUAD) patients with pathogenic alterations in EGFR, most patients develop acquired resistance to these agents via mechanisms enabling the sustained activation of the PI3K and MAPK oncog...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:JCI Insight
Päätekijät: Tohmé, Rita, Izadmehr, Sudeh, Gandhe, Sai, Tabaro, Giancarlo, Vallabhaneni, Sanjay, Thomas, Ava, Vasireddi, Neal, Dhawan, Neil S., Ma’ayan, Avi, Sharma, Neelesh, Galsky, Matthew D., Ohlmeyer, Michael, Sangodkar, Jaya, Narla, Goutham
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society for Clinical Investigation 2019
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6478418/
https://ncbi.nlm.nih.gov/pubmed/30830869
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.125693
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia